TrialBritish journal of haematology2013

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

Peter M Voorhees et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.